FindTrial
Sign In

Clinical Study on Prognostic Biomarkers of Esophageal Cancer

Clinical study of predicting esophageal squamous cell carcinoma tumor prognosis by single-cell transcriptome and spatial transcriptome sequencing of tumor tissue infiltrating immune cell subsets in different parts of tumor tissue

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036733
Enrollment
Unknown
Registered
2020-08-24
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

Gold Standard:Clinical outcome
Index test:Prognosis&#32
prediction&#32
model&#32
of&#32
esophageal&#32
carcinoma.

Sponsors

Xinhua Hospital affiliated to Shanghai Jiaotong University School
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with primary esophageal squamous cell carcinoma, without medication.

Exclusion criteria

Exclusion criteria: Nil

Design outcomes

Primary

MeasureTime frame
Tag genes of different immune cell subgroups;Enrichment score of each immune cell in different patients;Overal survival;Disease-free survival;SEN, SPE, ACC, AUC of ROC;—

Countries

China

Contacts

Public ContactYingxia Zheng
combi3230@163.com+86 21-25077075

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026